Company / SG&A Expense
Zoetis SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$2.4B
FY2025
5-year range
$1.6B / $2.4B
FY2021-FY2025
Trend
+2.6%
vs FY2024
Sector context
#13 of 213
Health Care
What the data says
Among 213 Health Care companies, Zoetis is in the bottom 6% for sg&a expense. SG&A Expense has increased for 5 consecutive years, from $1.5B in FY2020 to $2.4B in FY2025.
Based on SEC 10-K filings.
$2.4B in FY2025 with a 5-year CAGR of +9.9%. Top quartile in the Health Care sector.
Increased from $2.0B to $2.4B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +11.3%
- 5-Year CAGR
- +9.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 213This company $2.4B Sector average $722.3M
▼
+229.2% above sector average
Key checks
Key Insights
- Zoetis's sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +9.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 2.6% year-over-year.
- Ranks #13 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 28.2%
- Strong return on equity: 49.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4B | +2.6% |
| FY2024 | $2.3B | +15.8% |
| FY2023 | $2.0B | +15.9% |
| FY2022 | $1.7B | +5.4% |
| FY2021 | $1.6B | +10.4% |
| FY2020 | $1.5B | -9.4% |
| FY2019 | $1.6B | +10.4% |
| FY2018 | $1.5B | -3.1% |
| FY2017 | $1.5B | -6.8% |
| FY2016 | $1.6B | +1.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026